Madrigal Q3 Rezdiffra sales jump on strong demand, posts first profit
Overview
U.S. biopharma reported Q3 Rezdiffra sales up 50% yr/yr, first profitable quarter
Company nearly doubled Rezdiffra patient count from Q3 2025, reflecting strong adoption
Operating expenses fell, mainly due to lower R&D costs
Outlook
Company expects U.S. F2-F3 MASH market to grow over 30% by year-end 2026
Madrigal plans to initiate MAESTRO-CSPH Phase 3 trial for F4c MASH in first half of 2027
MAESTRO-NASH OUTCOMES trial data expected in late 2027
Result Drivers
REZDIFFRA DEMAND - Co said Q3 revenue growth was driven by increased U.S. demand for Rezdiffra
PRESCRIBER ADOPTION - Co attributed patient growth and sales to deepening prescriber adoption and high patient demand
MARKET EXPANSION - Co said the addressable U.S. F2-F3 MASH market is accelerating, on track for more than 30% growth by YE26
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Product Revenue | $431.27 mln | ||
Q3 EPS | $1.83 | ||
Q3 Net Income | $55.44 mln | ||
Q3 Operating Expenses | $375.28 mln | ||
Q3 Operating Income | $55.99 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Madrigal Pharmaceuticals, Inc. is $670.00, about 55.4% above its November 2 closing price of $431.16
The stock recently traded at 108 times the next 12-month earnings vs. a P/E of 253 three months ago
Reuters Recommended Reads
Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand
Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised
Nov 2 - Krystal Biotech Q3 product revenue rises 30% on VYJUVEK demand
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)